Dipeptidyl Peptidase IV in Inflammatory Bowel Diseases (DPP IV/CD26)

Open access

Dipeptidil-peptidaza IV (DPP IV/CD26) i upalne bolesti crijeva

Upalne bolesti crijeva (Crohnova bolest, ulcerozni kolitis, nedeterminirani kolitis) skupina su kroničnih autoimunosnih upalnih bolesti obilježenih ponavljanim upalama različitih dijelova gastrointestinalnog trakta koje su važan javnozdravstveni problem današnjice. Unatoč brojnim temeljnim i kliničkim istraživanjima etiologija ovih bolesti, kao i sama patogeneza upale ostaju nedovoljno razjašnjene. Dosadašnja su istraživanja potvrdila uzročno-posljedičnu vezu između medijatora upalnog odgovora i molekula uključenih u regulaciju njihove biološke aktivnosti, osobito proteaza. Cilj ovoga preglednog rada jest sažeti prikaz dosadašnjih saznanja o različitim aspektima upalnih bolesti crijeva, s posebnim naglaskom na potencijalnu ulogu i uključenost dipeptidil-peptidaze IV, odnosno molekule CD26 (DPP IV/CD26) u mehanizme nastanka upalnih procesa u probavnom sustavu. Dan je i pregled životinjskih modela kolitisa koji su znatno pridonijeli razumijevanju i terapiji ovih bolesti, s osobitim naglaskom na mišji model ulceroznog kolitisa (DSS-kolitis) te Crohnove bolesti (TNBS-kolitis).

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Hanauer SB. Inflammatory bowel disease: epidemiology pathogenesis and therapeutic opportunities. Inflamm Bowel Dis 2006;12(Suppl 1):S3-9.

  • Repiso A Alcantara M Munoz-Rosas C Rodriguez-Merlo R Perez-Grueso MJ Carrobles JM Carrobles JM Martinez-Potenciano JL. Extraintestinal manifestations of Crohn's disease: prevalence and related factors. Rev Esp Enferm Dig 2006;98:510-7.

  • Sands BE Grabert S. Epidemiology of inflammatory bowel disease and overview of pathogenesis. Med Health R I 2009;92:73-7.

  • Hibi T. Molecular biological studies of the pathogenesis in inflammatory bowel disease. Intern Med 2003;42:285-7.

  • Geboes K Colombel JF Greenstein A Jewell DP Sandborn WJ Vatn MH Warren B Riddell RH.; Pathology Task Force of the International Organization of Inflammatory Bowel Diseases. Indeterminate colitis: a review of the concept - what's in a name? Inflamm Bowel Dis 2008;14:850-7.

  • Fatahzadeh M. Inflammatory bowel disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;108:e1-10.

  • Baticic L Detel D Kucic N Buljevic S Pugel EP Varljen J. Neuroimmunomodulative properties of dipeptidyl peptidase IV/CD26 in a TNBS-induced model of colitis in mice. J Cell Biochem 2011;112:3322-33.

  • Hildebrandt M Rose M Rüter J Salama A Mönnikes H Klapp BF. Dipeptidyl peptidase IV (DP IV CD26) in patients with inflammatory bowel disease. Scand J Gastroenterol 2001;36:1067-72.

  • Varljen J Mijandrušić Sinčić B Batičić L Varljen N Detel D Lekić A. Clinical relevance of the serum dipeptidyl peptidase IV (DPP IV/CD26) activity in adult patients with Crohn's disease and ulcerative colitis. Croat Chem Acta 2005;78:427-32.

  • Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence prevalence and environmental influences. Gastroenterology 2004;126:1504-17.

  • Baumgart DC Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627-40.

  • Niv Y Abuksis G Fraser GM. Epidemiology of ulcerative colitis in Israel: a survey of Israeli kibbutz settlements. Am J Gastroenterol 2000;95:693-8.

  • Baumgart DC Bernstein CN Abbas Z Colombel JF Day AS D'Haens G Dotan I Goh KL Hibi T Kozarek RA Quigley EM Reinisch W Sands BE Sollano JD Steinhart AH Steinwurz F Vatn MH Yamamoto-Furusho JK. IBD Around the world: Comparing the epidemiology diagnosis and treatment: Proceedings of the World Digestive Health Day 2010 - Inflammatory bowel disease task force meeting. Inflamm Bowel Dis 2011;17:639-44.

  • Sands BE. Inflammatory bowel disease: past present and future. J Gastroenterol 2007;42:16-25.

  • Sincić BM Vucelić B Persić M Brncić N Erzen DJ Radaković B Mićović V Stimac D. Incidence of inflammatory bowel disease in Primorsko-goranska County Croatia 2000-2004: A prospective population-based study. Scand J Gastroenterol 2006;41:437-44.

  • Molodecky NA Kaplan GG. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol 2010;6:339-46.

  • Shivananda S Lennard-Jones J Logan R Fear N Price A Carpenter L van Blakenstein M. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996;39:690-7.

  • Van Limbergen J Russell RK Nimmo ER Satsangi J. The genetics of inflammatory bowel disease. Am J Gastroenterol 2007;102:2820-31.

  • Satsangi J Morecroft J Shah NB Nimmo E. Genetics of inflammatory bowel disease: scientific and clinical implications. Best Pract Res Clin Gastroenterol 2003;17:3-18.

  • Abreu MT. The pathogenesis of inflammatory bowel disease: translational implications for clinicians. Curr Gastroenterol Rep 2002;4:481-9.

  • Hendrickson BA Gokhale R Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 2002;15:79-94.

  • Noble C Nimmo E Gaya D Russell RK Satsangi J. Novel susceptibility genes in inflammatory bowel disease. World J Gastroenterol 2006;12:1991-9.

  • Bouma G Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521-33.

  • Hugot JP Chamaillard M Zouali H Lesage S Cezard JP Belaiche J Almer S Tysk C O'Morain CA Gassull M Binder V Finkel Y Cortot A Modigliani R Puig LP Rousseau GC Macry J Colombel JF Sahbatou M Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.

  • Ogura Y Bonen DK Inohara N Nicolae DL Chen FF Ramos R Britton H Moran T Karaliuskas R Duerr RH Achkar J-P Brant SR Bayless TM Kirschner BS Hanauer SB Nuñez G Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.

  • Van Limbergen J Russell RK Nimmo ER Ho GT Arnott ID Wilson DC Satsangi J. Genetics of the innate immune response in inflammatory bowel disease. Inflamm Bowel Dis 2007;13:338-55.

  • Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.

  • Colletti T. IBD - recognition diagnosis therapeutics. JAAPA 2004;17:16-18 21-14.

  • Farrell RJ LaMont JT. Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am 2002;31:41-62.

  • MacDonald TT. Gastrointestinal inflammation. Inflammatory bowel disease in knockout mice. Curr Biol 1994;4:261-3.

  • Rath HC Schultz M Freitag R Dieleman LA Li F Linde HJ Schölmerich J Balfour Sartor R. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001;69:2277-85.

  • Cucchiara S Iebba V Conte MP Schippa S. The microbiota in inflammatory bowel disease in different age groups. Dig Dis 2009;27:252-8.

  • Klement E Lysy J Hoshen M Avitan M Goldin E Israeli E. Childhood hygiene is associated with the risk for inflammatory bowel disease: a population-based study. Am J Gastroenterol 2008;103:1775-82.

  • Swidsinski A Loening-Baucke V Herber A. Mucosal flora in Crohn's disease and ulcerative colitis - an overview. J Physiol Pharmacol 2009;60(Suppl 6):61-71.

  • Sanz Y De Palma G. Gut microbiota and probiotics in modulation of epithelium and gut-associated lymphoid tissue function. Int Rev Immunol 2009;28:397-413.

  • Shah SA Feller ER. Inflammatory bowel disease. Med Health R I 2009;92:72.

  • Sonnenberg A. Occupational mortality of inflammatory bowel disease. Digestion 1990;46:10-8.

  • Kaplan GG Hubbard J Korzenik J Sands BE Panaccione R Ghosh S Wheeler AJ Villeneuve PJ. The inflammatory bowel diseases and ambient air pollution: a novel association. Am J Gastroenterol 2010;105:2412-9.

  • Henderson P van Limbergen JE Schwarze J Wilson DC. Function of the intestinal epithelium and its dysregulation in inflammatory bowel disease. Inflamm Bowel Dis 2011;17:382-95.

  • Yamamoto T Nakahigashi M Saniabadi AR. Review article: diet and inflammatory bowel disease - epidemiology and treatment. Aliment Pharmacol Ther 2009;30:99-112.

  • Persson PG Ahlbom A Hellers G. Diet and inflammatory bowel disease: a case-control study. Epidemiology 1992;3:47-52.

  • Wall R Ross RP Fitzgerald GF Stanton C. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev 2010;68:280-9.

  • Cosnes J. What is the link between the use of tobacco and IBD? Inflamm Bowel Dis 2008;14(Suppl 2):S14-15.

  • van der Heide F Dijkstra A Weersma RK Albersnagel FA van der Logt EM Faber KN Sluiter WJ Kleibeuker JH Dijkstra G. Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2009;15:1199-207.

  • Carbonnel F Jantchou P Monnet E Cosnes J. Environmental risk factors in Crohn's disease and ulcerative colitis: an update. Gastroenterol Clin Biol 2009;33(Suppl 3):S145-57.

  • Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol 2004;18:481-96.

  • Lakatos PL. Environmental factors affecting inflammatory bowel disease: have we made progress? Dig Dis 2009;27:215-25.

  • Peters CA Cesaretti JA Stone NN Stock RG. Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease. Int J Radiat Oncol Biol Phys 2006;66:424-9.

  • Broom OJ Widjaya B Troelsen J Olsen J Nielsen OH. Mitogen activated protein kinases: a role in inflammatory bowel disease? Clin Exp Immunol 2009;158:272-80.

  • Garg P Vijay-Kumar M Wang L Gewirtz AT Merlin D Sitaraman SV. Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis. Am J Physiol Gastrointest Liver Physiol 2009;296:G175-84.

  • Mentlein R. Cell-surface peptidases. Int Rev Cytol 2004;235:165-213.

  • Matteucci E Giampietro O. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr Med Chem 2009;16:2943-51.

  • Van der Veken P Haemers A Augustyns K. Prolyl peptidases related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery. Curr Topics Med Chem 2007;7:621-35.

  • Sedo A Malik R. Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochim Biophys Acta 2001;1550:107-16.

  • Cordero OJ Salgado FJ Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother 2009;58:1723-47.

  • Levy MT McCaughan GW Abbott CA Park JE Cunningham AM Müller E Rettig WJ Gorrell MD. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology 1999;29:1768-78.

  • Henry LR Lee HO Lee JS Klein-Szanto A Watts P Ross EA Chen WT Cheng JD. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 2007;13:1736-41.

  • Rettig WJ Garin-Chesa P Healey JH Su SL Ozer HL Schwab M Albino AP Old LJ. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res 1993;53:3327-35.

  • Niedermeyer J Kriz M Hilberg F Garin-Chesa P Bamberger U Lenter MC Park J Viertel B Püschner H Mauz M Rettig WJ Schnapp A. Targeted disruption of mouse fibroblast activation protein. Mol Cell Biol 2000;20:1089-94.

  • Abbott CA Yu DM Woollatt E Sutherland GR McCaughan GW Gorrell MD. Cloning expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog DPP8. Eur J Biochem 2000;267:6140-50.

  • Dubois V Van Ginneken C De Cock H Lambeir AM Van der Veken P Augustyns K Chen X Scharpé S De Meester I. Enzyme activity and immunohistochemical localization of dipeptidyl peptidase 8 and 9 in male reproductive tissues. J Histochem Cytochem 2009;57:531-41.

  • Chen T Smyth D Abbott CA. Cd26. J Biolo Regul Homeost Agents 2004;18:47-54.

  • Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci 2005;108:277-92.

  • Boonacker E Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 2003;82:53-73.

  • Liu Z Christensson M Forslöw A De Meester I Sundqvist KG. A CD26-controlled cell surface cascade for regulation of T cell motility and chemokine signals. J Immunol 2009;183:3616-24.

  • Vanderheyden M Bartunek J Goethals M Verstreken S Lambeir AM De Meester I Scharpé S. Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside. Clin Chem Lab Med 2009;47:248-52.

  • Hopsu-Havu VK Glenner GG. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie 1966;7:197-201.

  • Morrison ME Vijayasaradhi S Engelstein D Albino AP Houghton AN. A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med 1993;177:1135-43.

  • Lojda Z. Studies on glycyl-proline naphthylamidase. I. Lymphocytes. Histochemistry 1977;54:299-309.

  • Kullertz G Fischer G Barth A. [Catalytic mechanism of dipeptidyl-peptidase IV in German]. Acta Biol Med Ger 1978;37:559-67.

  • Hanski C Huhle T Reutter W. Involvement of plasma membrane dipeptidyl peptidase IV in fibronectin-mediated adhesion of cells on collagen. Biol Chem Hoppe Seyler 1985;366:1169-76.

  • Mentlein R. Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides. Regul Pept 1999;85:9-24.

  • Darmoul D Lacasa M Baricault L Marguet D Sapin C Trotot P Barbat A. Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation. J Biol Chem 1992;267:4824-33.

  • Ishii T Ohnuma K Murakami A Takasawa N Kobayashi S Dang NH Schlossman SF Morimoto C. CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. Proc Natl Acad Sci U S A 2001;98:12138-43.

  • Rosenblum JS Kozarich JW. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol 2003;7:496-504.

  • Shipp MA Look AT. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key! Blood 1993;82:1052-70.

  • Gorrell MD Gysbers V McCaughan GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 2001;54:249-64.

  • Fleischer B. CD26: a surface protease involved in T-cell activation. Immunol Today 1994;15:180-4.

  • Muñoz E Blazquez MV Madueño JA Rubio G Peña J. CD26 induces T-cell proliferation by tyrosine protein phosphorylation. Immunology 1992;77:43-50.

  • Bednarczyk JL Carroll SM Marin C McIntyre BW. Triggering of the proteinase dipeptidyl peptidase IV (CD26) amplifies human T lymphocyte proliferation. J Cell Biochem 1991;46:206-18.

  • Bühling F Junker U Reinhold D Neubert K Jäger L Ansorge S. Functional role of CD26 on human B lymphocytes. Immunol Lett 1995;45:47-51.

  • Kahne T Lendeckel U Wrenger S Neubert K Ansorge S Reinhold D. Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth (review). Int J Mol Med 1999;4:3-15.

  • Fleischer B Sturm E De Vries JE Spits H. Triggering of cytotoxic T lymphocytes and NK cells via the Tp103 pathway is dependent on the expression of the T cell receptor/CD3 complex. J Immunol 1988;141:1103-7.

  • Jacobs R Stoll M Stratmann G Leo R Link H Schmidt RE. CD16- CD56+ natural killer cells after bone marrow transplantation. Blood 1992;79:3239-44.

  • Bühling F Kunz D Reinhold D Ulmer AJ Ernst M Flad HD Ansorge S. Expression and functional role of dipeptidyl peptidase IV (CD26) on human natural killer cells. Nat Immun 1994;13:270-9.

  • Abbott CA Baker E Sutherland GR McCaughan GW. Genomic organization exact localization and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics 1994;40:331-8.

  • Böhm SK Gum JR Jr. Erickson RH Hicks JW Kim YS. Human dipeptidyl peptidase IV gene promoter: tissue-specific regulation from a TATA-less GC-rich sequence characteristic of a housekeeping gene promoter. Biochem J 1995;311(Pt 3):835-43.

  • Misumi Y Hayashi Y Arakawa F Ikehara Y. Molecular cloning and sequence analysis of human dipeptidyl peptidase IV a serine proteinase on the cell surface. Biochim Biophys Acta 1992;1131:333-6.

  • Engel M Hoffmann T Wagner L Wermann M Heiser U Kiefersauer R Huber R Bode W Demuth H-U Brandstetter H. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc Natl Acad Sci U S A 2003;100:5063-8.

  • Rasmussen HB Branner S Wiberg FC Wagtmann N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol 2003;10:19-25.

  • Bjelke JR Christensen J Branner S Wagtmann N Olsen C Kanstrup AB Rasmussen HB. Tyrosine 547 constitutes an essential part of the catalytic mechanism of dipeptidyl peptidase IV. J Biol Chem 2004;279:34691-7.

  • Van Damme J Struyf S Wuyts A Van Coillie E Menten P Schols D Sozzani S De Meester I Proost P. The role of CD26/DPP IV in chemokine processing. Chem Immunol 1999;72:42-56.

  • Hoffmann T Faust J Neubert K Ansorge S. Dipeptidyl peptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences. FEBS Lett 1993;336:61-4.

  • Vanhoof G Goossens F De Meester I Hendriks D Scharpé S. Proline motifs in peptides and their biological processing. Faseb J 1995;9:736-44.

  • Wang XM Yu DM McCaughan GW Gorrell MD. Extra-enzymatic roles of DPIV and FAP in cell adhesion and migration on collagen and fibronectin. Adv Exp Med Biol 2006;575:213-22.

  • Martinez-Navio JM Climent N Pacheco R Garcia F Plana M Nomdedeu M Oliva H Rovira C Miralles L Gatell JM Gallart T Mallol J Lluis C Franco R. Immunological dysfunction in HIV-1-infected individuals caused by impairment of adenosine deaminase-induced costimulation of T-cell activation. Immunology 2009;128:393-404.

  • Pang R Law WL Chu AC Poon JT Lam CS Chow AK Ng L Cheung LW Lan XR Lan HY Tan VP Yau TC Poon RT Wong BC. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 2010;6:603-15.

  • Ansorge S Bank U Heimburg A Helmuth M Koch G Tadje J Lendeckel U Wolke C Neubert K Faust J Fuchs P Reinhold D Thielitz A Täger M. Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med 2009;47:253-61.

  • Reinhold D Goihl A Wrenger S Reinhold A Kühlmann UC Faust J Neubert K Thielitz A Brocke S Täger M Ansorge S Bank U. Review: Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice. Clin Chem Lab Med 2009;47:268-74.

  • De Meester I Scharpé S Lambeir AM. Dipeptidyl peptidases and related proteins: multifaceted markers and therapeutic targets. Clin Chem Lab Med 2009;47:245-7.

  • Schön E Eichmann E Grunow R Jahn S Kiessig ST Volk HD Ansorge S. Dipeptidyl peptidase IV in human T lymphocytes. An approach to the role of a membrane peptidase in the immune system. Biomed Biochim Acta 1986;45:1523-8.

  • Reinhold D Kähne T Steinbrecher A Wrenger S Neubert K Ansorge S Brocke S. The role of dipeptidyl peptidase IV (DP IV) enzymatic activity in T cell activation and autoimmunity. Biol Chem 2002;383:1133-8.

  • Franco R Valenzuela A Lluis C Blanco J. Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. Immunol Rev 1998;161:27-42.

  • Pacheco R Martinez-Navio JM Lejeune M Climent N Oliva H Gatell JM Gallart T Mallol J Lluis C Franco R. CD26 adenosine deaminase and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc Natl Acad Sci U S A 2005;102:9583-8.

  • Thompson MA Ohnuma K Abe M Morimoto C Dang NH. CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders. Mini Rev Med Chem 2007;7:253-73.

  • Aytac U Dang NH. CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy. Curr Drug Targets Immune Endocr Metabol Disord 2004;4:11-8.

  • Yazbeck R Howarth GS Abbott CA. Dipeptidyl peptidase inhibitors an emerging drug class for inflammatory disease? Trends Pharmacol Sci 2009;30:600-7.

  • Lambeir AM Durinx C Scharpé S De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties functions and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-94.

  • Blonde L. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleve Clin J Med 2009;76(Suppl 5):S4-11.

  • Campbell RK Neumiller JJ White J Sisson E Kuhn C. Type 2 diabetes: epidemiology and treatment pathophysiology new therapeutics and the evolving role of the pharmacist. J Am Pharm Assoc 2009;49(Suppl 1):S2.

  • Palalau AI Tahrani AA Piya MK Barnett AH. DPP-4 inhibitors in clinical practice. Postgrad Med 2009;121:70-100.

  • Ahrén B. GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. Curr Diab Rep 2007;7:340-7.

  • Lupi R Del Guerra S D'Aleo V Boggi U Filipponi F Marchetti P. The direct effects of GLP-1 and GIP alone or in combination on human pancreatic islets. Regul Pept 2010;165:129-32.

  • Hildebrandt M Reutter W Arck P Rose M Klapp BF. A guardian angel: the involvement of dipeptidyl peptidase IV in psychoneuroendocrine function nutrition and immune defence. Clin Sci 2000;99:93-104.

  • Bank U Bohr UR Reinhold D Lendeckel U Ansorge S Malfertheiner P Tager M. Inflammatory bowel diseases: multiple benefits from therapy with dipeptidyl- and alanyl-aminopeptidase inhibitors. Front Biosci 2008;13:3699-713.

  • Matsumoto S Okabe Y Setoyama H Takayama K Ohtsuka J Funahashi H Imaoka A Okada Y Umesaki Y. Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain. Gut 1998;43:71-8.

  • Hartmann B Thulesen J Kissow H Thulesen S Orskov C Ropke C Poulsen SS Holst JJ. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology 2000;141:4013-20.

  • Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology 2001;142:521-7.

  • Estall JL Drucker DJ. Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharmaceut Design 2006;12:1731-50.

  • Drucker DJ Yusta B Boushey RP DeForest L Brubaker PL. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol 1999;276:G79-91.

  • Tsai CH Hill M Asa SL Brubaker PL Drucker DJ. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol 1997;273:E77-84.

  • Drucker DJ Shi Q Crivici A Sumner-Smith M Tavares W Hill M DeForest L Cooper S Brubaker PL. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nature Biotechnol 1997;15:673-7.

  • Yan S Marguet D Dobers J Reutter W Fan H. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. Eur J Immunol 2003;33:1519-27.

  • Sadlack B Merz H Schorle H Schimpl A Feller AC Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253-61.

  • Kühn R Löhler J Rennick D Rajewsky K Müller W Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263-74.

  • Elson CO Sartor RB Tennyson GS Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344-67.

  • Scheiffele F Fuss IJ. Induction of TNBS colitis in mice. Curr Prot Immunol 2002;Chapter 15: Unit 15.19.

  • Uhlig HH Powrie F. Mouse models of intestinal inflammation as tools to understand the pathogenesis of inflammatory bowel disease. Eur J Immunol 2009;39:2021-6.

  • Grisham MB Volkmer C Tso P Yamada T. Metabolism of trinitrobenzene sulfonic acid by the rat colon produces reactive oxygen species. Gastroenterology 1991;101:540-7.

  • Ardite E Sans M Panés J Romero FJ Piqué JM Fernández-Checa JC. Replenishment of glutathione levels improves mucosal function in experimental acute colitis. Lab Invest 2000;80:735-44.

  • Wirtz S Neurath MF. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 2007;59:1073-83.

  • Hans W Schölmerich J Gross V Falk W. The role of the resident intestinal flora in acute and chronic dextran sulfate sodium-induced colitis in mice. Eur J Gastroenterol Hepatol 2000;12:267-73.

  • Axelsson LG Landström E Bylund-Fellenius AC. Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine. Aliment Pharmacol Ther 1998;12:925-34.

  • Murthy SN Cooper HS Shim H Shah RS Ibrahim SA Sedergran DJ. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci 1993;38:1722-34.

  • Murthy S Cooper HS Yoshitake H Meyer C Meyer CJ Murthy NS. Combination therapy of pentoxifylline and TNFalpha monoclonal antibody in dextran sulphate-induced mouse colitis. Aliment Pharmacol Ther 1999;13:251-60.

  • Ohkusa T. [Production of experimental ulcerative colitis in hamsters by dextran sulfate sodium and changes in intestinal microflora in Japanese]. Nippon Shokakibyo Gakkai Zasshi 1985;82:1327-36.

  • Okayasu I Hatakeyama S Yamada M Ohkusa T Inagaki Y Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990;98:694-702.

  • Yamada M Ohkusa T Okayasu I. Occurrence of dysplasia and adenocarcinoma after experimental chronic ulcerative colitis in hamsters induced by dextran sulphate sodium. Gut 1992;33:1521-27.

  • Egger B Bajaj-Elliott M MacDonald TT Inglin R Eysselein VE Buchler MW. Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion 2000;62:240-8.

  • Bailey RW Bourne EJ. Intracellular glycosidases of dextran-producing bacteria. Nature 1961;191:277-8.

  • Kitajima S Takuma S Morimoto M. Histological analysis of murine colitis induced by dextran sulfate sodium of different molecular weights. Exp Anim 2000;49:9-15.

  • Venkatraman A Ramakrishna BS Pulimood AB Patra S Murthy S. Increased permeability in dextran sulphate colitis in rats: time course of development and effect of butyrate. Scand J Gastroenterol 2000;35:1053-9.

  • Poritz LS Garver KI Green C Fitzpatrick L Ruggiero F Koltun WA. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. J Surg Res 2007;140:12-9.

  • Ni J Chen SF Hollander D. Effects of dextran sulphate sodium on intestinal epithelial cells and intestinal lymphocytes. Gut 1996;39:234-41.

  • Chen Y Chou K Fuchs E Havran WL Boismenu R. Protection of the intestinal mucosa by intraepithelial gamma delta T cells. Proc Natl Acad Sci U S A 2002;99:14338-43.

  • Cooper HS Murthy SN Shah RS Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993;69:238-49.

  • Lambeir AM Durinx C Proost P Van Damme J Scharpe S De Meester I. Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion. FEBS Lett 2001;507:327-30.

  • Mentlein R Dahms P Grandt D Krüger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 1993;49:133-44.

  • Bouras M Huneau JF Luengo C Erlanson-Albertsson C Tomé D. Metabolism of enterostatin in rat intestine brain membranes and serum: differential involvement of proline-specific peptidases. Peptides 1995;16:399-405.

  • Nausch I Mentlein R Heymann E. The degradation of bioactive peptides and proteins by dipeptidyl peptidase IV from human placenta. Biol Chem Hoppe Seyler 1990;371:1113-8.

  • Durinx C Lambeir AM Bosmans E Falmagne JB Berghmans R Haemers A Scharpé S De Meester I. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem 2000;267:5608-13.

  • Kato T Nagatsu T Fukasawa K Harada M Nagatsu I Sakakibara S. Successive cleavage of N-terminal Arg1-Pro2 and Lys3-Pro4 from substance P but no release of Arg1-Pro2 from bradykinin by X-Pro dipeptidyl-aminopeptidase. Biochim Biophys Acta 1978;525:417-22.

  • Heymann E Mentlein R. Liver dipeptidyl aminopeptidase IV hydrolyzes substance P. FEBS Lett 1978;91:360-4.

  • Shane R Wilk S Bodnar RJ. Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV. Brain Res 1999;815:278-86.

  • Oravecz T Pall M Roderiquez G Gorrell MD Ditto M Nguyen NY Boykins R Unsworth E Norcross MA. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 1997;186:1865-72.

  • Proost P De Meester I Schols D Struyf S Lambeir AM Wuyts A Opdenakker G De Clercq E Scharpé S Van Damme J. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem 1998;273:7222-7.

  • Shioda T Kato H Ohnishi Y Tashiro K Ikegawa M Nakayama EE Hu H Kato A Sakai Y Liu H Honjo T Nomoto A Iwamoto A Morimoto C Nagai Y. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci U S A 1998;95:6331-6.

  • Proost P Struyf S Schols D Opdenakker G Sozzani S Allavena P Mantovani A Augustyns K Bal G Haemers A Lambeir AM Scharpé S Van Damme J De Meester I. Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem 1999;274:3988-93.

  • Struyf S Proost P Schols D De Clercq E Opdenakker G Lenaerts JP Detheux M Parmentier M De Meester I Scharpé S Van Damme J. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol 1999;162:4903-9.

  • Mentlein R Gallwitz B Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide glucagon-like peptide-1(7-36)amide peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-35.

  • Bongers J Lambros T Ahmad M Heimer EP. Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochim Biophys Acta 1992;1122:147-53.

Search
Journal information
Impact Factor

IMPACT FACTOR 2018: 1.436
5-year IMPACT FACTOR: 1.606

CiteScore 2018: 1.53

SCImago Journal Rank (SJR) 2018: 0.358
Source Normalized Impact per Paper (SNIP) 2018: 0.608

Cited By
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 603 372 17
PDF Downloads 153 98 6